Abstract:BackgroundSecond generation antipsychotics such as risperidone are first-line pharmacotherapy treatment choices for schizophrenia. However, our ability to reliably predict and monitor treatment reaction is impeded by the lack of relevant biomarkers. As a biomarker for the susceptibility of schizophrenia and clozapine treatment response, DNA methylation (DNAm) has been studied, but the impact of antipsychotics on DNAm has not been explored in drug-naïve patients.ObjectiveThe aim of the present study was to examine changes of DNAm after short-term antipsychotic therapy in first-episode drug-naïve schizophrenia (FES) to identify the beneficial and adverse effect of risperidone on DNAm and their relation to treatment outcome.MethodsThirty-eight never treated schizophrenia patients and 38 demographically matched individuals (healthy controls) were assessed at baseline and at 8-week follow-up with symptom ratings, and cognitive and functional imaging procedures, at which time a blood draw for DNAm studies was performed. During the 8-week period, patients received treatment with risperidone monotherapy. An independent data set was used as replication.ResultsWe identified brain related pathways enriched in 4,888 FES-associated CpG sites relative to controls. Risperidone administration in patients altered DNAm in 5,979 CpG sites relative to baseline. Significant group differences in DNAm at follow-up were seen in FES patients at 6,760 CpG sites versus healthy controls. Through comparison of effect size, we found 87.54% out of the risperidone-associated changes in DNAm showed possible beneficial effect, while only 12.46% showed potential adverse effect. There were 580 DNAm sites in which changes shifted methylation levels to be indistinguishable from controls after risperidone treatment. The DNAm changes of some sites that normalized after treatment were correlated with treatment-related changes in symptom severity, spontaneous neurophysiological activity, and cognition. We replicated our results in an independent data set.ConclusionThe normalizing effect of risperidone monotherapy on gene DNAm, and its correlation with clinically relevant phenotypes, indicates that risperidone therapy is associated with DNAm changes that are related to changes in brain physiology, cognition and symptom severity.

Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone

Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study

Risperidone-induced changes in DNA methylation from peripheral blood in first-episode schizophrenia parallel neuroimaging and cognitive phenotype

Effects of Depression on the Cytokine Profile in Drug Naïve First-Episode Psychosis

Risperidone-induced Topological Alterations of Anatomical Brain Network in First-Episode Drug-Naive Schizophrenia Patients: a Longitudinal Diffusion Tensor Imaging Study

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Effects of Antipsychotic Treatment on S100B and Oxidative Stress in Patients with Schizophrenia

Effect of resperidone treatment on serum levels of nonenzymatic antioxidant in drug-na?ve first-episode schizophrenic patients

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal Fmri Study

BDNF in Antipsychotic Naive First Episode Psychosis: Effects of Risperidone and the Immune-Inflammatory Response System.

Effects of risperidone monotherapy on the default-mode network in antipsychotic-naïve first-episode schizophrenia: Posteromedial cortex heterogeneity and relationship with the symptom improvements.

The effect of risperidone treatment on superoxide dismutase in schizophrenia

Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study

Effects of Risperidone and Haloperidol on Superoxide Dismutase and Nitric Oxide in Schizophrenia

Activation of the Immune-Inflammatory Response System and the Compensatory Immune-Regulatory System in Antipsychotic Naive First Episode Psychosis.

Lowered Paraoxonase 1 (PON1) Activity is Associated with Increased Cytokine Levels in Drug Naïve First Episode Psychosis

A Dissociation in Effects of Risperidone Monotherapy on Functional and Anatomical Connectivity Within the Default Mode Network

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study

Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone

Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes

An Open-Label Randomised Comparison of Aripiprazole, Olanzapine and Risperidone for the Acute Treatment of First-Episode Schizophrenia: Eight-week Outcomes.